Provided by Tiger Trade Technology Pte. Ltd.

Larimar Therapeutics, Inc.

3.12
-0.4300-12.11%
Post-market: 3.140.0200+0.64%17:30 EST
Volume:2.73M
Turnover:9.05M
Market Cap:267.04M
PE:-1.60
High:3.56
Open:3.56
Low:3.12
Close:3.55
52wk High:6.91
52wk Low:1.61
Shares:85.59M
Float Shares:45.15M
Volume Ratio:1.47
T/O Rate:6.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9534
EPS(LYR):-1.3159
ROE:-78.24%
ROA:-42.99%
PB:1.92
PE(LYR):-2.37

Loading ...

Company Profile

Company Name:
Larimar Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
65
Office Location:
Three Bala Plaza East,Suite 506,Bala Cynwyd,Pennsylvania,United States
Zip Code:
19004
Fax:
- -
Introduction:
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Directors

Name
Position
Peter Barrett
Chairman of the Board
Thomas E. Hughes
President, Chief Executive Officer and Director
Bruce Booth
Director
Cameron Geoffrey McDonough
Director
Frances K. Heller
Director
Frank E. Thomas
Director
John L. LaMattina
Director
Robert J. Perez
Director
Thomas O. Daniel
Director

Shareholders

Name
Position
Thomas E. Hughes
President, Chief Executive Officer and Director
Patricia L. Allen
Chief Financial Officer
Dennis D. Kim
Chief Medical Officer